Skip to main content
SpringerLink
Log in

Neurological Complications of Chemotherapy

  • Chapter
  • First Online:
Central Nervous System Metastases

Abstract

As the outcomes for many cancers have improved, treatment-related toxicities and their impact on quality of life have become a more important part of oncologic care. Numerous chemotherapy regimens are associated with undesirable effects on the nervous system, often requiring modification of the treatment plan or even discontinuation of the offending drug. This chapter explores the neurotoxicities associated with certain chemotherapeutic agents, focusing on those that produce frequent or unique neurological complications; only cytotoxic treatments are reviewed, since targeted therapies and immunotherapies are discussed elsewhere. Drugs affecting predominantly the central nervous system are presented first, followed by the most common sources of chemotherapy-induced peripheral neuropathy. A description of the clinical characteristics and, when available, diagnostic and treatment strategies are included, to provide the reader with tools to recognize and manage these complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol. 1986;22:815–9.

    Article  CAS  PubMed  Google Scholar 

  2. Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anti-Cancer Drugs. 2004;15:347–50.

    Article  CAS  PubMed  Google Scholar 

  3. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–80.

    Article  CAS  PubMed  Google Scholar 

  4. Tajino T, Kikuchi SI, Yamada H, Takeda A, Konno SI. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. J Orthop Sci. 2010;15:104–11.

    Article  CAS  PubMed  Google Scholar 

  5. Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract. 2015;21:188–93.

    Article  CAS  PubMed  Google Scholar 

  6. Sweiss KI, Beri R, Shord SS. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. Drug Saf. 2008;31:989–96.

    Article  CAS  PubMed  Google Scholar 

  7. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003;65(Suppl 2):11–6.

    Article  CAS  PubMed  Google Scholar 

  8. Taupin D, Racela R, Friedman D. Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. Clin EEG Neurosci. 2014;45:222–5.

    Article  PubMed  Google Scholar 

  9. Feyissa AM, Tummala S. Ifosfamide related encephalopathy: the need for a timely EEG evaluation. J Neurol Sci. 2014;336:109–12.

    Article  CAS  PubMed  Google Scholar 

  10. Savica R, Rabinstein AA, Josephs KA. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol. 2011;258:1729–31.

    Article  CAS  PubMed  Google Scholar 

  11. Ames B, Lewis LD, Chaffee S, Kim J, Morse R. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624–6.

    PubMed  Google Scholar 

  12. Gonzalez-Angulo AM, Orzano JA, Davila E. Ifosfamide-induced encephalopathy. South Med J. 2002;95:1215–7.

    Article  PubMed  Google Scholar 

  13. Richards A, Marshall H, McQuary A. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract. 2011;17:372–80.

    Article  CAS  PubMed  Google Scholar 

  14. McDonnell AM, Rybak I, Wadleigh M, Fisher DC. Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy. J Oncol Pharm Pract. 2012;18:436–9.

    Article  CAS  PubMed  Google Scholar 

  15. Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, Adelstein DJ, Brown RA, Coccia PF, Strandjord S. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927–32.

    Article  CAS  PubMed  Google Scholar 

  16. de la Sainz MCS, Jiménez Martín A, de Felipe Mimbrera A, Corral Corral Í. Cerebellar toxicity due to cytarabine: a series of 4 cases. Neurologia. 2016;31:491–2.

    Article  Google Scholar 

  17. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997;15:833–9.

    Article  CAS  PubMed  Google Scholar 

  18. Honkaniemi J, Kähärä V, Dastidar P, et al. Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology. 2000;42:895–9.

    Article  CAS  PubMed  Google Scholar 

  19. Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K, Tomoyasu S. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol. 2007;82:304–6.

    Article  PubMed  Google Scholar 

  20. Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA. High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR Am J Neuroradiol. 1993;14:1014–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Hoffman DL, Howard JR, Sarma R, Riggs JE. Encephalopathy, myelopathy, optic neuropathy, and anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol. 1993;16:258–62.

    Article  CAS  PubMed  Google Scholar 

  22. Chutorian AM, Bojko A, Heier L, Frucht S, Nygaard T, Edelberg D. Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment. J Child Neurol. 2003;18:812–5.

    Article  PubMed  Google Scholar 

  23. Nevill TJ, Benstead TJ, McCormick CW, Hayne OA. Horner’s syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside. Am J Hematol. 1989;32:314–5.

    Article  CAS  PubMed  Google Scholar 

  24. Openshaw H, Slatkin NE, Stein AS, Hinton DR, Forman SJ. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer. 1996;78:1899–905.

    Article  CAS  PubMed  Google Scholar 

  25. Resar LMS, Phillips PC, Kastan MB, Leventhal BG, Bowman PW, Civin CI. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer. 1993;71:117–23.

    Article  CAS  PubMed  Google Scholar 

  26. Pound CM, Keene DL, Udjus K, Humphreys P, Johnston DL. Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2007;29:183–6.

    Article  CAS  PubMed  Google Scholar 

  27. Legrand F, Dorgeret S, Saizou C, Duval M, Vilmer E. Cerebellar herniation after intrathecal chemotherapy including cytosine arabinoside in a boy with T acute lymphoblastic leukemia. Leukemia. 2002;16:2454–5.

    Article  CAS  PubMed  Google Scholar 

  28. Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214–8.

    Article  CAS  PubMed  Google Scholar 

  29. Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, Panizo C, Martínez-Vila E. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neuro-Oncol. 2011;103:603–9.

    Article  CAS  Google Scholar 

  30. Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, Grem JL, Allegra CJ, Diasio RB, Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.

    CAS  PubMed  Google Scholar 

  31. Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother. 2000;34:35–8.

    Article  CAS  PubMed  Google Scholar 

  32. Suresh P, Kapoor R, Kapur BN. Irreversible cerebellar toxicity after infusional 5-fluorouracil therapy. Indian J Cancer. 2015;52:627–8.

    Article  CAS  PubMed  Google Scholar 

  33. Martinez-Lapiscina EH, Erro ME, Cabada T, Tuñón T. 5-fluorouracil induced hyperammonemic encephalophathy: etiopathologic correlation. Can J Neurol Sci. 2012;39:553–4.

    Article  CAS  PubMed  Google Scholar 

  34. Lucato LT, McKinney AM, Short J, Teksam M, Truwit CL. Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol. 2006;50:364–8.

    Article  CAS  PubMed  Google Scholar 

  35. Li J, Lee JJ, Chu E, Baehring JM. Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion. Clin Colorectal Cancer. 2012;11:215–7.

    Article  PubMed  Google Scholar 

  36. Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16:328–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Videnovic A, Semenov I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology. 2005;65:1792–4; discussion 1685.

    Article  CAS  PubMed  Google Scholar 

  38. Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:300–8.

    Article  CAS  PubMed  Google Scholar 

  39. Lee MS, McKinney AM, Brace JR, Santacruz K. Clinical and imaging features of fludarabine neurotoxicity. J Neuroophthalmol. 2010;30:37–41.

    Article  PubMed  Google Scholar 

  40. Helton KJ, Patay Z, Triplett BM. Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:729–31.

    Article  CAS  PubMed  Google Scholar 

  41. Saumoy M, Castells G, Escoda L, Marés R, Richart C, Ugarriza A. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma. 2002;43:433–6.

    Article  PubMed  Google Scholar 

  42. Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol. 2002;70:51–4.

    Article  PubMed  Google Scholar 

  43. Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Agarwal A, Vijay K, Thamburaj K, Ouyang T. Transient leukoencephalopathy after intrathecal methotrexate mimicking stroke. Emerg Radiol. 2011;18:345–7.

    Article  PubMed  Google Scholar 

  45. Inaba H, Khan RB, Laningham FH, Crews KR, Pui C-H, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008;19:178–84.

    Article  CAS  PubMed  Google Scholar 

  46. Patterson DM, Aries J, Hyare H, Holder D, Rees J, Lee SM. Nonconvulsive status epilepticus and leucoencephalopathy after high-dose methotrexate. J Clin Oncol. 2011;29:e459–61.

    Article  PubMed  Google Scholar 

  47. Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, Yoshida M, Kaneda M, Suzuki Y, Miyasaka K. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology. 2003;45:493–7.

    Article  CAS  PubMed  Google Scholar 

  48. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004;62:548–55.

    Article  CAS  PubMed  Google Scholar 

  49. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology. 2004;62:451–6.

    Article  PubMed  Google Scholar 

  50. Cavaliere R, Schiff D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep. 2006;6:218–26.

    Article  CAS  PubMed  Google Scholar 

  51. Iuvone L, Mariotti P, Colosimo C, Guzzetta F, Ruggiero A, Riccardi R. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer. 2002;95:2562–70.

    Article  PubMed  Google Scholar 

  52. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neuro-Oncol. 2015;122:391–8.

    Article  CAS  Google Scholar 

  53. Yi Y, Kang HJ, Shin HY, Kim K. Progressive myelopathy mimicking subacute combined degeneration after intrathecal chemotherapy. J Child Neurol. 2015;30:246–9.

    Article  PubMed  Google Scholar 

  54. Murata K, Maeba A, Yamanegi M, Nakanishi I, Ito H. Methotrexate myelopathy after intrathecal chemotherapy: a case report. J Med Case Rep. 2015;9:135.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Shintaku M, Toyooka N, Koyama T, Teraoka S, Tsudo M. Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case. Neuropathology. 2014;34:547–53.

    Article  CAS  PubMed  Google Scholar 

  56. Dicuonzo F, Salvati A, Palma M, Lefons V, Lasalandra G, De Leonardis F, Santoro N. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol. 2009;24:1013–8.

    Article  PubMed  Google Scholar 

  57. Antunes NL, Souweidane MM, Lis E, Rosenblum MK, Steinherz PG. Methotrexate leukoencephalopathy presenting as Klüver-Bucy syndrome and uncinate seizures. Pediatr Neurol. 2002;26:305–8.

    Article  PubMed  Google Scholar 

  58. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, Donati MB. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216–22.

    Article  CAS  PubMed  Google Scholar 

  59. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, Deangelo DJ, Silverman LB. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452–9.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Böhles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25:484–7.

    Article  PubMed  Google Scholar 

  61. Alsaid Y, Gulab S, Bayoumi M, Baeesa S. Cerebral sinus venous thrombosis due to asparaginase therapy. Case Rep Hematol. 2013;2013:841057.

    PubMed  PubMed Central  Google Scholar 

  62. Hourani R, Abboud M, Hourani M, Khalifeh H, Muwakkit S. L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics. 2008;39:46–50.

    Article  CAS  PubMed  Google Scholar 

  63. Frantzeskaki F, Rizos M, Papathanassiou M, Nikitas N, Lerikou M, Armaganidis A, Dimopoulos G. L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. Am J Case Rep. 2013;14:311–4.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34:934–8.

    Article  CAS  PubMed  Google Scholar 

  65. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007;130:1076–88.

    Article  CAS  PubMed  Google Scholar 

  66. Oldenburg J, Kraggerud SM, Brydøy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007;5:70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82:51–77.

    Article  PubMed  Google Scholar 

  68. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998;101:2842–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992;69:203–7.

    Article  CAS  PubMed  Google Scholar 

  70. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990;66:1117–23.

    Article  CAS  PubMed  Google Scholar 

  71. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014:CD005228.

    Google Scholar 

  72. Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol. 2016;2016:1809394.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer. 1980;45:764–6.

    Article  CAS  PubMed  Google Scholar 

  75. Cisplatin neurotoxicity. N Engl J Med. 1990;323:64–5.

    Google Scholar 

  76. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Cerrud-Rodriguez RC, Quinteros MG, Azam M. Internal carotid artery occlusion and stroke as a complication of cisplatin-based chemotherapy for metastatic testicular germ cell tumour. BMJ Case Rep. 2017;2017:bcr-2017–220084.

    Google Scholar 

  78. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119:438–44.

    Article  CAS  PubMed  Google Scholar 

  79. Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol. 2015;33:3416–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008;61:105–11.

    Article  CAS  PubMed  Google Scholar 

  81. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27:992–1002.

    Article  CAS  PubMed  Google Scholar 

  82. Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998;64:667–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol. 2007;18:608–9.

    Article  CAS  PubMed  Google Scholar 

  84. Fischer N, Stuermer J, Rodic B, Pless M. Carboplatin-induced bilateral papilledema: a case report. Case Rep Oncol. 2009;2:67–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. Toxics. 2015;3:152–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996;47:115–8.

    Article  CAS  PubMed  Google Scholar 

  88. Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118:5171–8.

    Article  PubMed  Google Scholar 

  89. Shin YS, Min KJ, Choi SY, Lee NW. Non-convulsive seizure related to Cremophor EL™-free, polymeric micelle formulation of paclitaxel: a case report. Obstet Gynecol Sci. 2018;61:421–4.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996;46:1596–9.

    Article  CAS  PubMed  Google Scholar 

  91. Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MFK, Jacobs C, Ong M, Clemons M. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer. 2016;24:3633–50.

    Article  PubMed  Google Scholar 

  92. van den Bent MJ, Hilkens PHE, Sillevis Smitt PAE, van Raaij-van den Aarssen VJ, Bontenbal M, Verweij J. Lhermitte’s sign following chemotherapy with docetaxel. Neurology. 1998;50:563–4.

    Article  CAS  PubMed  Google Scholar 

  93. Moloney TP, Xu W, Rallah-Baker K, Oliveira N, Woodward N, Farrah JJ. Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. BMC Ophthalmol. 2014;14:18.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Vahdat LT, Thomas ES, Roché HH, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012;20:2661–8.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Egerton N. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer Chemother Pharmacol. 2010;66:1005–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P, Sparano JA. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140:341–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Mora E, Smith EML, Donohoe C, Hertz DL. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res. 2016;6:2416–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Verstappen CCP, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64:1076–7.

    Article  CAS  PubMed  Google Scholar 

  99. Hancock BW, Naysmith A. Vincristine-induced autonomic neuropathy. Br Med J. 1975;3:207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Trobaugh-Lotrario AD, Smith AA, Odom LF. Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol. 2003;40:39–43.

    Article  PubMed  Google Scholar 

  101. Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, Walsh TJ. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55:290–7.

    Article  CAS  PubMed  Google Scholar 

  102. Dixit G, Dhingra A, Kaushal D. Vincristine induced cranial neuropathy. J Assoc Physicians India. 2012;60:56–8.

    PubMed  Google Scholar 

  103. Latiff ZA, Kamal NA, Jahendran J, Alias H, Goh BS, Syed Zakaria SZ, Jamal R. Vincristine-induced vocal cord palsy: case report and review of the literature. J Pediatr Hematol Oncol. 2010;32:407–10.

    Article  PubMed  Google Scholar 

  104. Dhingra D, Sethi GR, Mantan M. Unilateral phrenic nerve palsy: a rare manifestation of vincristine neurotoxicity. Indian J Pediatr. 2014;81:957–8.

    Article  PubMed  Google Scholar 

  105. Adhikari S, Dongol RM, Hewett Y, Shah BK. Vincristine-induced blindness: a case report and review of literature. Anticancer Res. 2014;34:6731–3.

    PubMed  Google Scholar 

  106. Escuro RS, Adelstein DJ, Carter SG. Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine. Cleve Clin J Med. 1992;59:643–4.

    Article  CAS  PubMed  Google Scholar 

  107. Ozyurek H, Oguz G, Ozen S, Akyuz C, Karli Oguz K, Anlar B, Aysun S. Reversible posterior leukoencephalopathy syndrome: report of three cases. J Child Neurol. 2005;20:990–3.

    Article  PubMed  Google Scholar 

  108. Hennipman B, de Vries E, Bökkerink JPM, Ball LM, Veerman AJP. Intrathecal vincristine: 3 fatal cases and a review of the literature. J Pediatr Hematol Oncol. 2009;31:816–9.

    Article  PubMed  Google Scholar 

  109. Pace A, Bove L, Nisticò C, Ranuzzi M, Innocenti P, Pietrangeli A, Terzoli E, Jandolo B. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry. 1996;61:409–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010;51:1178–87.

    Article  CAS  PubMed  Google Scholar 

  111. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895–903.

    Article  CAS  PubMed  Google Scholar 

  112. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–53.

    Article  CAS  PubMed  Google Scholar 

  113. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40.

    Article  PubMed  Google Scholar 

  114. Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan TH. Bortezomib-associated demyelinating neuropathy-clinical and pathologic features. J Clin Neuromuscul Dis. 2015;16:202–9.

    Article  PubMed  Google Scholar 

  115. Oshikawa G, Kojima A, Doki N, Kobayashi T, Kakihana K, Tsuda H, Endo I, Kamata N, Ohashi K, Sakamaki H. Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma. Intern Med. 2013;52:111–4.

    Article  PubMed  Google Scholar 

  116. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–34.

    Article  CAS  PubMed  Google Scholar 

  118. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007;69:573–81.

    Article  CAS  PubMed  Google Scholar 

  119. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschlüter M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132:584–93.

    Article  CAS  PubMed  Google Scholar 

  120. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27:1788–93.

    Article  CAS  PubMed  Google Scholar 

  121. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–52.

    Article  CAS  PubMed  Google Scholar 

  122. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Maria Diaz

  2. University of Virginia Neuro-Oncology Center, Charlottesville, VA, USA

    David Schiff

Authors
  1. Maria Diaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Schiff .

Editor information

Editors and Affiliations

  1. Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA

    Manmeet Ahluwalia

  2. Department of Neurosurgery and Neuro-Oncology, Clairval Hospital Center, Ramsay-Générale de Santé, Marseille, France, Neurophysiopathology Institute, Aix-Marseille Université, Marseille, France

    Philippe Metellus

  3. Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy

    Riccardo Soffietti

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Diaz, M., Schiff, D. (2020). Neurological Complications of Chemotherapy. In: Ahluwalia, M., Metellus, P., Soffietti, R. (eds) Central Nervous System Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-23417-1_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-23417-1_26

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-23416-4

  • Online ISBN: 978-3-030-23417-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation